Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1,4-Butanediol SCHEMBL924160 | 0.94 | CA2 (0.37) | CA2TSHRTDP1CAMK2A | |
| 1,5-Pentanediol SCHEMBL923631 | 0.91 | GPR84 (0.38) | CA2TSHRTDP1 | |
| Ethylene Glycol SCHEMBL921115 | 0.87 | CA2 (0.41) | CA2TSHRTDP1 | |
| Ethylene Glycol SCHEMBL7202667 | 0.87 | CA2 (0.41) | CA2TSHRTDP1 | |
| Sulfuric Acid SCHEMBL920405 | 0.79 | CA5A (0.50) | CA2TSHRTDP1CAMK2A | |
| Sulfuric Acid SCHEMBL710960 | 0.79 | CA5A (0.50) | CA2TSHRTDP1CAMK2A | |
| SCHEMBL56331 | 0.79 | CA2 (0.54) | CA2TSHRTDP1 | |
| SCHEMBL3781 | 0.79 | — | — | |
| SCHEMBL29039846 | 0.78 | CA2 (0.32) | CA2 | |
| Sulfuric Acid SCHEMBL28086717 | 0.76 | CA5A (0.46) | CA2TSHRTDP1CAMK2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130296434-A1 | FORMULATIONS AND METHODS FOR TREATING AMYLOIDOSIS | KIACTA SARL (CA) | 2013-11-07 | — | — | US | claimed |
| US-20110002875-A1 | METHOD FOR TREATING AMYLOIDOSIS | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2011-01-06 | — | — | US | claimed |
| US-20030108595-A1 | Method for treating amyloidosis | QUEEN'S UNIVERSITY AT KINGSTON | 2003-06-12 | — | — | US | claimed |
| US-20010048941-A1 | Method for treating amyloidosis | QUEEN'S UNIVERSITY OF KINGSTON | 2001-12-06 | — | — | US | claimed |
| WO-1999045947-A9 | IN VITRO FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | UNIV WASHINGTON (US) | 2000-03-02 | — | — | WO | claimed |
| US-5643562-A | ANTIDEPOSIT AGENTS FOR PROTEINS FOR MEDICAL DIAGNOSIS OF DISEASES | QUEEN'S UNIVERSITY OF KINGSTON (CA) | 1997-07-01 | — | — | US | claimed |
| EP-2944308-A1 | Formulations and methods for treating chronic infection | Kiacta Sàrl (CH) | 2015-11-18 | — | — | EP | disclosed |
| EP-2156181-B1 | PEPTIDE PROBES FOR DIAGNOSTICS AND THERAPEUTICS | ADLYFE INC (US) | 2015-11-04 | — | — | EP | disclosed |
| EP-1885350-B9 | FORMULATIONS AND METHODS FOR TREATING AMYLOIDOSIS | KIACTA S RL (CH) | 2015-06-17 | — | — | EP | disclosed |
| EP-1885350-B1 | FORMULATIONS AND METHODS FOR TREATING AMYLOIDOSIS | KIACTA S RL (CH) | 2015-03-04 | — | — | EP | disclosed |
| US-20140155480-A1 | Scyllo-Inositol Derivatives and Their Use in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation of Amyloid Formation, Deposition, Accumulation for Persistence | WARATAH PHARMACEUTICALS INC. (CA) | 2014-06-05 | — | — | US | disclosed |
| US-20140135403-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF OCULAR DISEASES | WARATAH PHARMACEUTICALS INC. (CA) | 2014-05-15 | — | — | US | disclosed |
| US-8673579-B2 | Peptide probes for diagnostics and therapeutics | ADLYFE, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-5858326-A | CONTACTING AMYLOIDOGENIC PEPTIDE WITH AMYLOID-ENHANCING COMPOUND COMPRISING AROMATIC MOIETY AND AT LEAST TWO ANIONIC MOIETIES IN VITRO TO FORM AMYLOID FIBRILS | NEUROCHEM, INC. (CA) | 1999-01-12 | — | — | US | disclosed |
| US-5840294-A | INHIBITING AMYLOID DEPOSITION BY ADMINISTERING A THERAPEUTIC COMPOUND COMPRISING AN ANIONIC GROUP AND A CARRIER MOLECULE | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1998-11-24 | — | — | US | disclosed |
| US-5728375-A | ADMINISTERING A COMPOUND COMPRISING AN ANIONIC GROUP AND A CARRIER MOLECULE; INHIBITS DEPOSITION BY PREVENTING INTERACTION BETWEEN AN AMYLOIDOGENIC PROTEIN AND A BASEMENT MEMBRANE CONSTITUENT | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1998-03-17 | — | — | US | disclosed |
| EP-0814842-A1 | METHOD FOR TREATING AMYLOIDOSIS | Queen's University at Kingston (CA) | 1998-01-07 | — | — | EP | disclosed |
| US-5643562-A | ANTIDEPOSIT AGENTS FOR PROTEINS FOR MEDICAL DIAGNOSIS OF DISEASES | QUEEN'S UNIVERSITY OF KINGSTON (CA) | 1997-07-01 | — | — | US | disclosed |
| WO-1996039129-A1 | METHODS OF INCREASING AMYLOID DEPOSITION | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1996-12-12 | — | — | WO | disclosed |
| WO-1996028187-A1 | METHOD FOR TREATING AMYLOIDOSIS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 1996-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030108595-A1 | Method for treating amyloidosis | TTR, IAPP, APP | CA2 716/4885TSHR 3807/4885TDP1 3343/4885 |
| US-20010048941-A1 | Method for treating amyloidosis | TTR, APOB, NEFM | CA2 821/4885TSHR 3883/4885TDP1 4164/4885 |
| US-20140135403-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF OCULAR DISEASES | APP, IAPP, TTR | CA2 1094/4885TSHR 1412/4885TDP1 2475/4885 |
| US-20140155480-A1 | Scyllo-Inositol Derivatives and Their Use in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation of Amyloid Formation, Deposition, Accumulation for Persistence | SCLY, SCO2, SGMS2 | CA2 2349/4885TSHR 703/4885TDP1 3296/4885 |
| US-20110002875-A1 | METHOD FOR TREATING AMYLOIDOSIS | TTR, IAPP, APP | CA2 716/4885TSHR 3807/4885TDP1 3343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.